Muhammad Umair Mushtaq: TIL Therapy Holds Potential for Growth in Advanced Melanoma
Muhammad Umair Mushtaq, Associate Professor Hematologic Malignancies and Cellular Therapeutics at the University of Kansas Medical Center, shared a post on X:
“TIL Therapy Holds Potential for Growth in Advanced Melanoma.”
Tumor-infiltrating lymphocyte (TIL) therapy is emerging as a promising, personalized immunotherapy option for patients with advanced melanoma, according to Muhammad Umair Mushtaq, MD. Speaking at the 2025 Immune Cell Effector Therapy (ICE-T) Conference, Mushtaq discussed the current landscape of TIL therapy in metastatic melanoma. As the only approved cellular therapy for solid cancers, TIL therapy stands out for its potential to harness a patient’s own immune cells to target and fight cancer.
Mushtaq, an associate professor of Medicine in the Division of Hematologic Malignancies and Cellular Therapeutics at the University of Kansas Medical Center, highlighted encouraging long-term results. Approximately one-third of patients receiving TIL therapy respond to treatment, and notably, about 20% of these patients maintain their response even four years after treatment. This durability underscores the therapy’s potential as a meaningful option for those with limited alternatives in advanced melanoma care.
More posts featuring Muhammad Umair Mushtaq.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023